Monitor for any future committee assignments or strategic shifts that may reflect Mr. Davis's healthcare diagnostics expertise. No immediate financial or operational read-through from this board addition.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 10 $324.29entry
- T+1 · 7d ago −1.70%α −3.01% · $318.79
- T+5 · 14h ago −2.08%α +0.25% · $317.54
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Stryker announced the nomination of James E. Davis, Chairman, CEO and President of Quest Diagnostics, to its board of directors, effective January 1, 2027. The board was expanded from 11 to 12 members to accommodate his election. This is a routine board addition with no financial terms disclosed.
Key Facts
- Board of Directors increased authorized directors from 11 to 12 and elected James E. Davis to fill the vacancy
- Mr. Davis's election becomes effective January 1, 2027
- Mr. Davis is Chairman, CEO and President of Quest Diagnostics
- Mr. Davis will be compensated consistent with other non-employee directors as described in the 2026 proxy statement
- No committee assignments have been made for Mr. Davis at this time
Financial Impact
No financial impact disclosed; director compensation consistent with standard non-employee director pay
Risk Factors
- No material risks identified from this routine board appointment
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-453635 |
| Document: d101928dex991.htm | 0001193125-26-453635 |
| Document: 0001193125-26-453635-index-headers.html | 0001193125-26-453635 |
| Document: 0001193125-26-453635-index.html | 0001193125-26-453635 |
| Document: 0001193125-26-453635.txt | 0001193125-26-453635 |
Track record
29 reports on SYK
5 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +23.40% at T+20 after the Oct 7, 2026 report. 7 of 11 went positive at some point.
Filters
- Nov 12, 20266d ago Court Ruling Neutral 3/10 Entry $309.64 Now $310.72 +0.35% settles Dec 14
- Nov 9, 20268d ago 8-K Neutral 2/10 Viewing Entry $324.29 Now $310.72 −4.18% settles Dec 9
- Nov 5, 202612d ago 144 Neutral 3/10 Entry $325.87 Now $310.72 −4.65% settles Dec 7
- Nov 4, 202613d ago S-3ASR Neutral 3/10 Entry $335.08 Now $310.72 −7.27% settles Dec 4
- Nov 3, 202614d ago Institutional Cluster Mixed 3/10 Entry $310.55 Now $310.72 +0.05% settles Dec 2
- Oct 29, 202619d ago 8-K Bearish 6/10 No price data
- Oct 29, 202619d ago Press Release Bearish 6/10 Entry $291.86 Now $310.72 −6.46% settles Nov 30
- Oct 26, 202622d ago Press Release Neutral 4/10 Entry $306.13 Now $310.72 +1.50% settles Nov 23
- Oct 20, 202629d ago PTAB Trial Bearish 5/10 Entry $297.60 Now $310.72 −4.41% settles Nov 18
- Oct 7, 20265w ago ANALYST-UPGRADE Bullish 4/10 Entry $275.25 to $339.65 Now $310.72 +12.89% ▲ +23.40% +24.74% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers